1071 results about "Thelial cell" patented technology

The invention discloses a 3D intestinal organ differentiation method based on human pluripotent stem cells and an induction culture medium and application thereof, and relates to the technical field of stem cells. According to a culture medium formula combination, intestinal organs can be differentiated into various cell types such as epithelial cells, neuroendocrine cells and endothelial cells; the method is a key mark for successful differentiation and functional maturation of intestinal organs. According to the 3D intestinal organ differentiation method disclosed by the invention, histological structures such as intestinal crypts are differentiated from intestinal organs generated by differentiation, and the intestinal organs can creep in a maintenance stage, so that the intestinal organs are changed from structural bionics to functional simulation, and the significance of the 3D intestinal organ differentiation method is far better than that of pure morphological simulation. Through a systematic culture medium formula, a clear operation process and a multi-stage induction strategy, the 3D intestinal organ with structural integrity, cell diversity and functional activity is successfully constructed, and the system provides an efficient, reliable and extensible in-vitro model platform for intestinal biological research and related application.

The invention belongs to the technical field of medical image detection, and particularly relates to an esophageal flora image intelligent detection method for risk prediction of gastroesophageal reflux disease, which comprises the following steps: acquiring flora images and clinical data, and constructing a perception network; quantifying flora displacement characteristics by using image registration; the method comprises the following steps of: extracting flora density, aggregation degree and fluorescence gradient characteristics by combining improved U-Net + + segmentation, fusing flora and epithelial cell lesion characteristics through space-time attention, generating a flora-host association map, constructing a flora dynamic evolution model by utilizing a space-time map convolutional network, predicting Barrett esophageal occurrence probability and flora diffusion trend, and predicting the occurrence probability of the Barrett esophagus. Calculating a lesion risk level through a flora imbalance quantification algorithm; in combination with reflux frequency and pH fluctuation, a flora-environment interaction model is used for simulating a field planting coefficient and correcting parameters, the parameters are transmitted to a diagnosis platform to deduce canceration risks, grading suggestions are triggered, and a visual report is generated. Therefore, the problems of long detection period, weak microscopic analysis capability and the like in the prior art are solved.

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

The invention discloses application of tannic acid combined triazole medicines in preparation of medicines for treating diseases caused by fungi, and belongs to the technical field of antifungal. A series of drug sensitive tests show that tannic acid lower than 3 [mu] g / ml has no influence on the activity of human vaginal epithelial cells, and after the tannic acid is combined with fluconazole, the tannic acid can significantly inhibit the growth activity of drug-resistant candida (including drug-resistant candida albicans and drug-resistant candida glabrata). In view of the natural property, wide source and low toxicity of tannic acid, the invention provides a new antifungal treatment strategy, and the tannic acid has important clinical application value for treating infection (such as vaginal candidiasis) caused by drug-resistant fungi, especially under the condition that the existing antifungal drugs are poor in effect. Therefore, the tannic acid combined triazole medicine can be used for preparing the medicine for treating diseases caused by fungi.

The invention relates to the technical field of biological medicine, in particular to a lactobacillus-sourced extracellular vesicle and application of the lactobacillus-sourced extracellular vesicle in prevention and treatment of necrotizing enterocolitis, the extracellular vesicle is prepared from lactobacillus, the lactobacillus is Lactobacillus rhamnosus GG, the strain is purchased in the American Center for Type Culture Collection, and the preservation number is ATCC 53103. The preparation method of the extracellular vesicles comprises the following steps: carrying out ultracentrifugation on a lactobacillus culture solution, removing thalli, then collecting supernate, carrying out primary microfiltration, taking micro-filtrate, carrying out differential centrifugation, resuspending precipitates by using PBS, then carrying out secondary microfiltration, collecting the micro-filtrate, carrying out density gradient centrifugation, and collecting a 30-45% interface vesicle layer. The invention discloses a synergistic effect mode between intestinal symbiotic flora and intestinal epithelial cell metabolic molecules for the first time, and the discovery is expected to construct a brand-new mechanism normal form for regulating the host intestinal barrier function by flora.

The invention discloses a mucosal epithelial cell targeted oral ROS response type nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The oral ROS response type nano-enzyme comprises Ce-CDs carbon dots and a betaine polymer, and the betaine polymer is coated on the surfaces of the Ce-CDs carbon dots to form nano-particles; the Ce-CCDs carbon dots are prepared by taking a metal cerium source and chlorogenic acid as raw materials through a pyrolysis method. Through structural innovation and function integration, the prepared nano-enzyme shows outstanding advantages in the aspects of catalytic activity, targeted delivery, collaborative treatment, industrial application and the like, a new technical scheme is provided for efficient and safe treatment of inflammatory bowel diseases, and the nano-enzyme has remarkable technical innovation and clinical application value.

The invention relates to the technical field of cell engineering, and particularly discloses a construction method and application of a sika deer immortalized renal epithelial cell line, and the construction method comprises the following steps: taking renal epithelial primary cells from healthy sika deer renal cortex tissues to obtain primary renal epithelial cells; treating the primary renal epithelial cells with trypsin to obtain a cell suspension; inoculating the cell suspension into a complete culture medium, and transfecting with lentivirus loaded with SV40 large T antigen genes to obtain transfected cells; 3 [mu] g / mL puromycin is applied to the transfected cells for selective culture, so that non-transfected cells are eliminated, and drug-resistant cells are obtained; carrying out continuous passage on the drug-resistant cells for at least 30 generations to obtain the immortalized renal epithelial cell line of the sika deer; according to the invention, through a specific action mechanism (inhibiting a p53 / pRb pathway and blocking cell cycle exit) of the SV40 large T antigen, a proliferation limit caused by inhibition of telomerase activity of primary cells of the cervidae animals is overcome, and a cell resource library capable of realizing continuous passage is established.

The invention provides an application of a lactobacillus paracasei IOB413 metagen in prevention of helicobacter pylori infection, and relates to the technical field of microorganisms. The lactobacillus paracasei IOB413 metaplasm can competitively occupy gastric epithelial cell adhesion sites to directly block the initial colonization of helicobacter pylori, so that infection preposed interception is realized, and the lactobacillus paracasei IOB413 metaplasm is suitable for early prevention of high-incidence people. The compound has dual mechanisms of site blocking and urease inhibition, and can cooperate with antibiotics to improve the eradication rate and reduce the drug resistance. Animal experiments show that the traditional Chinese medicine composition can reduce gastric mucosa proinflammatory factors in a dose-dependent manner, improve the activity of antioxidant enzymes, reduce lipid peroxidation products, relieve mucosa lesion, promote repair and reduce the risk of complications; moreover, gastrointestinal hormone disorder can be reversed, the digestive function is maintained, and related discomfort is relieved.

This invention discloses a strain of *Lactobacillus plantarum* Grx402 with the ability to promote intestinal absorption of short-chain fatty acids. *Lactobacillus plantarum* Grx402 was isolated from the intestines of long-lived individuals in Bama, Guangxi (CGMCC No. 28585). Using a Caco-2 cell model to construct an intestinal absorption model of short-chain fatty acids (SCFAs), it was found that *Lactobacillus plantarum* Grx402 can promote the absorption and transport of acetic acid, propionic acid, and butyric acid by intestinal epithelial cells, exhibiting excellent ability to promote intestinal absorption of short-chain fatty acids. It can be used to prepare dairy products or beverages that promote the intestinal absorption of short-chain fatty acids.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention discloses a preparation method and application of a conditioned culture solution for improving the development rate of bovine in-vitro embryos. The preparation method comprises the following steps: culturing immortalized bovine endometrial epithelial cells by using a DMEM / F12 cell culture solution containing 10% FBS, collecting the cell culture solution in the culture process, and filtering to obtain an immortalized bovine endometrial epithelial cell conditional culture solution, namely the conditional culture solution capable of improving the development rate of the bovine in-vitro embryos. The prepared conditioned culture solution can simulate a liquid environment of an in-vivo environment, is used for culturing in-vitro embryos such as parthenogenetic activated embryos and in-vitro fertilized embryos, improves the cleavage rate and blastocyst rate of the in-vitro embryos and improves the development rate of the in-vitro embryos of cattle.

The invention discloses a lipid nanoparticle, a targeted lipid nanoparticle, and a preparation method and application thereof. The lipid nanoparticle has a core-shell structure, the core is formed by PLGA nanoparticles containing drug molecules, and the shell is formed by raw materials including phospholipid, cholesterol and a modification material; wherein the PLGA nanoparticles containing the drug molecules are formed by raw materials comprising PLGA and the drug molecules; the mass ratio of the PLGA to the phospholipid is (1-5): 1; the mass ratio of the phospholipid to the cholesterol is (3-10): 1, and the mass ratio of the phospholipid to the modification material is (3-10): 1; the drug molecules are selected from one or more of insoluble drugs, water-soluble drugs, genes and proteins; and the modification material is PEG-DSPE (Polyethylene Glycol Distearoyl The hardness of the lipid nanoparticles can be regulated and controlled, and cellular uptake can be improved by regulating and controlling the hardness; the targeted lipid nanoparticles can better improve cellular uptake, promote intestinal epithelial cell absorption and improve oral curative effect.

The invention belongs to the technical field of biological medicines, and particularly discloses a novel application of Epiblastatin A in preparation of a medicine for relieving cisplatin-induced acute kidney injury. The application disclosed by the invention for the first time reveals that by inhibiting the activity of Casein Kinase 1 (CK1) kinase, Epiblastine A can obviously relieve renal dysfunction and kidney tissue structure damage caused by cis-platinum. Experiments prove that the compound can effectively reduce serum creatinine and urea nitrogen levels, significantly improve renal tubule pathological injury, down-regulate expression of renal injury early-stage specific biomarkers KIM-1 and NGAL, and definitely inhibit renal tubule epithelial cell apoptosis in an in-vitro model. The invention also provides a specific pharmaceutical composition containing the Epiblastin A and a preparation form of the specific pharmaceutical composition. The invention provides a brand new mechanism and a high-efficiency and low-toxicity treatment strategy for clinically preventing and treating cisplatin dosage-limited renal toxicity, and has important clinical application value.

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.

The invention discloses application of a neutralizing antibody of oncostatin M in preparation of a medicine for treating bronchial pulmonary dysplasia. The application proves that the intrauterine inflammation can cause BPD-like lung lesion to the filial generation mouse, and the OSM expression level in the mouse lung tissue one day after the intrauterine inflammation filial generation is grown is obviously higher than that of a control group; the OSM level of the BPD group is higher than that of the non-BPD group in the umbilical blood sample of the premature infant; in-vitro experiments show that the OSM treatment can cause lung epithelial cell injury; by dripping a recombined OSM neutralizing antibody into the nose of a newborn mouse, down-regulation of the OSM level in the lung of the mouse is realized, filial generation lung injury induced by the intrauterine inflammation can be repaired, and the OSM can be used as a treatment target of the BPD caused by the intrauterine inflammation.

The invention relates to the technical field of biomedical materials, in particular to a degradable zinc-based composite GBR film with the surface loaded with a nanometer electrostatic spinning fiber coating and preparation and application of the degradable zinc-based composite GBR film. According to the degradable zinc-based composite GBR membrane with the surface loaded with the nano electrostatic spinning fiber coating, the nano fiber coating is implanted into the surface of a zinc-based material such as zinc alloy by adopting an electrostatic spinning technology, and the degradable zinc-based composite GBR membrane with the surface loaded with the nano electrostatic spinning fiber coating can inhibit excessive release of zinc ions, improve biocompatibility of the zinc alloy and the like, promote osteoblast differentiation and promote angiogenesis. The electrostatic spinning coating on the surface of the zinc-based composite GBR membrane serves as a physical barrier to block invasion of epithelial cells and fibrocytes, and angiogenesis is promoted along with degradation of fibers and slow release of drugs; the porous zinc alloy and the like in the middle layer not only provide mechanical support, but also release zinc ions in the degradation process to achieve multiple functions of resisting bacteria and promoting osteogenesis.

The invention provides a composition for promoting differentiation of intestinal immune cells as well as a preparation method and application of the composition. According to the composition, 1, 3-dioleic acid-2-palmitic acid triglyceride and breast milk oligosaccharide are used in a combined manner, so that monocytes can be effectively promoted to differentiate into intestinal macrophages, and inflammation is reduced to a certain extent. After the monocytes are differentiated into the intestinal macrophages, the intestinal immune homeostasis and intestinal microbiota inflammatory response can be regulated, so that the mucosal immune homeostasis and intestinal epithelial cell barrier function are maintained. Therefore, the composition provided by the invention can improve the intestinal immune barrier by promoting the monocytes to differentiate into the intestinal macrophages, and provides a new thought for improving the early intestinal barrier of infants through nutritional supplement.

The invention relates to the technical field of biological medicine, in particular to a drug screening model construction method based on airway organs, a model and application. The construction method of the drug screening model of the airway organoid comprises the steps of obtaining 2D airway epithelial cells, culturing the airway organoid, establishing an airway organoid inflammation model and / or establishing an airway organoid mucus secretion / goblet cell metaplasia model. Wherein the model is established according to the culture mode of the airway organ in cooperation with a specific stimulant for proliferation and differentiation. Compared with a traditional animal model, the organ-like model is low in cost and short in construction period, can better simulate the pathological process, can realize airway organ-like culture and establishment of an inflammation model and a mucus secretion / goblet cell metaplasia model at the same time, and has a good application prospect in drug detection of asthma and COPD diseases.

The invention discloses an application of engineered citrobacter freundii in fermentation synthesis of a stable body. The engineered citrobacter freundii is citrobacter freundii overexpressing a polyphosphate kinase gene Ppk1. The stable body prepared by fermenting the engineered citrobacter freundii is rich in polyphosphates and polyamines, particularly, the content of the polyamines can be up to 21wt%, the polyphosphates in the stable body can store the polyamines in an ionic bond combination mode, the combined polyamines are insoluble in water, a natural anion coating is generated, and the stability of the stable body is improved. And the sustained-release tablet is not easily taken by intestinal epithelial cells, so that the sustained-release tablet has a certain sustained-release effect. The medicine prepared by taking the compound as a main active ingredient shows a remarkable curative effect in ulcerative colitis treatment, has the comprehensive effects of reducing oxidative stress, enhancing the anti-inflammatory ability of a body and regulating immunity, is suitable for patients of all ages, and has outstanding application value and market prospect.

The present invention relates to Akkermansia muciniphila Akk11 having the functions of regulating blood glucose and blood fat and the use thereof. Said Akkermansia muciniphila Akk11 is classified and named as Akkermansia muciniphila Akk11 with the accession number of CCTCC NO: M2024119. The strain uses mucin as the unique source of carbon element and nitrogen element, so as to control the basic regulatory systems of glucose and energy metabolism, protect the integrity of intestinal epithelial cells and mucus layers to exert a protective effect on metabolism, regulate the levels of blood glucose and blood fat, and remarkably relieve symptoms of metabolic disorders, and thus providing strategies and reference basis for the prevention and treatment of obesity.

The application discloses a construction method and application of an ovary cell line of Quasipaa spinosa. The method comprises the following steps: selecting metamorphosis period larva ovary tissue, disinfecting and obtaining the ovary tissue, and then using collagenase I digestion solution to digest the ovary tissue at 26 DEG C for 1 hour; after the tissue block adheres to the wall, using a low-osmotic-pressure complete culture medium to carry out primary culture at 25-27 DEG C, wherein the culture medium is 60% diluted DMEM / F12 culture medium containing 10%-15% fetal bovine serum; when the cell confluence degree is higher than 70%, using trypsin-EDTA to digest the cells for 1-2 minutes to subculture, and the subculture culture medium contains 30% cell conditional culture medium; and finally, the cells are cryopreserved through programmed cooling. The ovary epithelial cell line of Quasipaa spinosa is successfully established for the first time, the survival rate of the cells after recovery is high, and the karyotype is stable. The constructed cell line can be used for amphibian reproductive biology research, compound screening and in-vitro conservation of germplasm resources.

The invention discloses an application of knocking down intestinal epithelial cells Mysm1 in increasing secretion of 5-HT by the intestinal epithelial cells. The invention provides application of a substance capable of inhibiting Mysm1 gene expression and / or activity in promoting intestinal tract / intestinal epithelial cells to secrete 5-hydroxytryptamine. According to the invention, the synthesis amount of the 5-HT in the intestinal tract can be manually regulated and controlled, so that the functions of the 5-HT in intestinal brain communication, intestinal tract barrier and the like are regulated and controlled; a product for promoting intestinal epithelial cells to secrete 5-hydroxytryptamine can be prepared, so that the 5-HT function is productized, and the use is convenient.

The invention belongs to the technical field of genetic engineering, and particularly relates to application of miRNA related to cow mastitis. The invention provides an application of miR-320b in preparation of a medicine for treating dairy cow mastitis, the nucleotide sequence of the miR-320b is shown as SEQ ID NO.1, and the miR-320b is used for diagnosing the process of resisting Escherichia coli, E. coli type dairy cow mastitis. The miR-320b expression quantity of the miR-320b in the dairy cow mammary epithelial cells or E. coli type mammary tissue induced by lipopolysaccharide (LPS) is detected, and when the expression quantity of the miR-320b is obviously reduced, the miR-320b is prompted to have an anti-inflammatory function in the dairy cow mastitis.

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.

The invention discloses a porcine beta-defensin-3 gene core promoter as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The sequence of the core promoter is as shown in SEQ ID No.1, and the core promoter has remarkable promoter activity in porcine small intestine epithelial cells and can be regulated and controlled by nutrient substances sodium butyrate and glutamine. The invention also discloses a construction method for specifically amplifying the core promoter, which comprises the following steps: carrying out PCR (Polymerase Chain Reaction) amplification by taking porcine small intestine epithelial cell DNA (Deoxyribonucleic Acid) as a template, constructing a pMD-18T-pBD-3-P recombinant plasmid by taking upstream and downstream primers as shown in SEQ No.2-SEQ No.3, and amplifying by taking the recombinant plasmid as a template to obtain a core promoter fragment. The core promoter disclosed by the invention provides an excellent experimental system for researching a transcription regulation mechanism of the porcine beta-defensin-3 gene, the nutritional response characteristic of the core promoter provides a new platform for researching nutrition-immune interaction, and the core promoter has a wide application prospect in the field of healthy breeding of livestock and poultry.

The invention discloses a pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector as well as a construction method and application of the pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector. The construction method comprises the following steps: mixing an mCherry gene segment and an IRES2 gene segment which are respectively obtained by PCR (Polymerase Chain Reaction) amplification in equal mass, then carrying out fusion amplification to obtain an IRES2-mCherry fusion gene segment, and carrying out homologous recombination on the IRES2-mCherry fusion segment and a pCDNA-3xHA-hTERT linearization vector. On the basis of a pCDNA-3xHA-hTERT stent vector, a pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector with red fluorescence is successfully constructed, and the fusion expression vector can be used as a fusion expression vector of the pCDNA-3xHA-hTERT-IRES2. The construction method is simple and efficient, enzyme digestion is not needed, and the constructed pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector can be subsequently used for transfecting bovine endometrial epithelial cells, so that the immortalized bovine endometrial epithelial cells are obtained.

The invention relates to lactobacillus plantarum-derived inorganic polyphosphate and application thereof in promoting cell proliferation. The preparation method of the lactobacillus plantarum-derived inorganic polyphosphate comprises the following step: extracting from lactobacillus plantarum by using glass milk. According to the invention, long-chain PolyP (PolyPLp) with the chain length of about 250 phosphate residues is extracted and purified from lactobacillus plantarum by using glass milk. And the effect of promoting cell proliferation is proved. An IL-1beta-induced Caco-2 intestinal epithelial cell barrier injury model is utilized, it is found that PolyP has the function of relieving intestinal inflammation, the effect of PolyP has chain length dependence, and the action effect of PolyPLp is optimal.

Compositions for inhibiting lipoxygenase enzymes (e.g., human epithelial 12 / 15-lipoxygenase (12 / 15-LOX) are provided. Compositions according to certain embodiments include a first solvent, a second solvent and a lipoxygenase inhibitor. In certain instances, the lipoxygenase inhibitor is present in the composition (e.g., compositions formulated for intravenous administration) at a concentration of 30 mg / mL or greater. Methods for treating or preventing a lipoxygenase (e.g., human epithelial 12 / 15-lipoxygenase (12 / 15-LOX))-mediated disease or disorder are also provided.

The present invention relates to lipid nanoparticle (LNP) compositions, as well as diagnostic or therapeutic polynucleotides, such as TERT mRNA, that can be delivered in a formulation together with the LNP compositions to various tissue and cell types in the whole body of a mammal, such as, for example, TNP mRNA. Comprising stem cells, progenitor cells, germ cells, differentiated cells or terminally differentiated cells, cancer cells, endothelial cells, epithelial cells, splenic cells, hepatocells, kidney cells and / or osteoblasts, for example, for use in the diagnosis, prevention and / or treatment of a condition or disease.

Disclosed are methods for producing controlled endometrial organoids using micropatterning techniques, and methods for using endometrial cells or organoids for diagnostic and predictive purposes, and for optimizing IVF and other infertility-related treatments, including embryo transfer and intrauterine insemination (IUI). These organoids grow in a spatially controlled manner and exhibit less heterogeneity than organoids grown directly in a three-dimensional culture. The specification also describes methods for predicting the success of embryo transfer or other IVF-related treatments, optimizing embryo transfer, improving embryo implantation in the endometrium, and performing embryo transfer in subjects. These methods include culturing endometrial organoids or endometrial epithelial cells, and contacting the endometrial organoids or cells with one or more blast-like cells. In some embodiments, the endometrial organoids or cells include endometrial cells obtained from subjects undergoing or considering IVF-related treatment.